Skip to main content

Table 2 TIL increase during neoadjuvant letrozole in postmenopausal breast cancer patients (n = 106)

From: Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

 

Change

p

Overall increase, mean (range)

6.8 (− 39 to 60)

< 0.0001

Responders (n = 58)

3.2 (− 39 to 35)

0.10

Non-responders (n = 44)

10.6 (− 25 to 60)

< 0.0001

  1. TILs tumour-infiltrating lymphocytes
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us